News from janssen pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 01, 2012, 07:30 ET

Janssen colabora con Vertex en un estudio en fase 2 un régimen completamente oral para la hepatitis C

- Janssen anuncia una colaboración con Vertex en un estudio en fase 2 para la investigación de un régimen completamente oral de...

Nov 01, 2012, 07:30 ET
Nov 01, 2012, 07:30 ET

Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C

 Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated...

Oct 16, 2012, 06:23 ET

Twice-daily INCIVO® (Telaprevir), in Combination With Peginterferon Alfa and Ribavirin, is Effective in Treating People Living With Genotype-1 Chronic Hepatitis C Virus

NOT INTENDED FOR US JOURNALISTS - OPTIMIZE study results to be presented in late-breaking poster presentation at the American Association for...

Aug 30, 2012, 12:03 ET

Janssen Pharmaceuticals, Inc. announces RISPERDAL® consumer protection settlement with 36 states and the District of Columbia

 Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced a settlement and consent decree today with 36 states and the...

Aug 29, 2012, 08:00 ET

FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)...

Jul 10, 2012, 08:00 ET

Janssen Licenses Diabetes Research Programs From Evotec and Harvard University

Janssen Pharmaceuticals, Inc. (Janssen) announced today it has licensed exclusive access to a portfolio of small molecule and biologic research...

May 17, 2012, 13:50 ET

Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA® ER (tapentadol)...

Dec 13, 2011, 08:38 ET
Dec 12, 2011, 13:00 ET

Bahnbrechende VISTA-studie zeigt signifikante verbesserungen in der langzeit-gesamtüberlebensrate bei der therapie von bisher unbehandeltem multiplem myelom mit VELCADE® (bortezomib)

Die Vorteile von Bortezomib in Kombination mit Melphalan und Prednison (VMP) wurden bei zahlreichen Patientensubgruppen unabhängig von der...

Dec 12, 2011, 13:00 ET

L' importante studio VISTA ha dimostrato un vantaggio significativo di sopravvivenza a lungo termine in pazienti con mieloma multiplo di nuova diagnosi trattati con VELCADE(R) (bortezomib)

I benefici di bortezomib, associato a melphalan e a prednisone (VMP) sono stati osservati  in diversi sottogruppi di pazienti...

Dec 12, 2011, 13:00 ET
Dec 09, 2011, 06:14 ET

L'efficacité de VELCADE soutenue par de nouvelles donnees presentees lors du 53eme Congres Annuel de la Societe Americaine d'hematologie

Les donnés de suivi à cinq ans recueillies au cours d'une étude pivot portant sur l'utilisation de...

Dec 09, 2011, 03:00 ET

53.Jahrestagung der American Society of Hematology: Wachsende Evidenzgrundlage für VELCADE

Bahnbrechende 5-Jahres Nachbeobachtungsdaten zu VELCADE®  (Bortezomib) bei Patienten mit zuvor unbehandeltem multiplen Myelom...

Dec 09, 2011, 03:00 ET

Se construye la base de evidencias de VELCADE al tiempo que se presentan nuevos datos

- Se construye la base de evidencias de VELCADE al tiempo que se presentan nuevos datos en la 53 reunión anual de la American Society of...

Dec 08, 2011, 16:21 ET

Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765

 Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), announced today that it has executed...

Nov 10, 2011, 14:00 ET

Janssen Pharmaceutical Companies Launch Healthy Minds Initiative to Spur Neuroscience Collaboration and Support Millions Suffering from Brain Disorders

Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") today announced the launch of Healthy Minds, a comprehensive initiative to...

Nov 04, 2011, 13:43 ET

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke...

Oct 31, 2011, 08:00 ET

Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a supplemental New...

Sep 14, 2011, 09:00 ET
Janssen Pharmaceuticals, Inc. logo.  (PRNewsFoto/Janssen Pharmaceuticals, Inc.)

New Survey Shows Moderate-to-Severe Acute Pain is Widely Undertreated, Especially Among Older Adults

A new survey shows almost half (44%) of U.S. patients in outpatient settings received potentially inadequate relief of moderate-to-severe acute...